Products Categories
| CAS No.: | 127-07-1 |
|---|---|
| Name: | Hydroxyurea |
| Article Data: | 60 |
| Molecular Structure: | |
|
|
|
| Formula: | CH4N2O2 |
| Molecular Weight: | 76.055 |
| Synonyms: | Urea,hydroxy- (6CI,8CI,9CI);Biosupressin;Carbamohydroxamic acid;Carbamohydroximicacid;Carbamoyl oxime;Droxia;Hydrea;Hydreia;Hydroxycarbamide;Hydroxylamine, N-(aminocarbonyl)-;Hydura;Hydurea;Onco-Carbide;Oxyrea;Oxyurea; |
| EINECS: | 204-821-7 |
| Density: | 1.457 g/cm3 |
| Melting Point: | 135-140 °C |
| Boiling Point: | 136.04°C (rough estimate) |
| Solubility: | water: 50 mg/mL |
| Appearance: | off-white crystalline solid |
| Hazard Symbols: |
 T, Xn
|
| Risk Codes: | 46-63-61-40 |
| Safety: | 53-36/37-45-36-22 |
| PSA: | 75.35000 |
| LogP: | 0.13510 |
- 144851-82-1METHYL2-AMINO-3-FLUOROBENZOATE
- 483366-12-7(2S,4R)-1-Boc-2-cyano-4-hydroxypyrrolidine
- 173606-50-3BOC-10-AMINODECANOIC ACID
- 361456-36-2METHYL (R)-(+)-ISOCYANATO-3-PHENYLPROPI&
- 5156-58-1N-(1-Benzyl-4-pipperidinyl)-N-phenylpropanamide HCl
- 81281-59-67-Benzylideneaminotheophylline
- 50288-62-5threo-Phenyl-2-piperidyl acetamide
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 47087-37-6Z-D-Glu-OMe
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 126669-78-1
N-(trimethylsiloxy)-N,N'-bis(trimethylsilyl)urea
- 127-07-1
N-hydroxyurea
| Conditions | Yield |
|---|---|
| With ethanol | 96% |
- 126669-76-9
N-(trimethylsiloxy)-N'-(trimethylsilyl)urea
- 127-07-1
N-hydroxyurea
| Conditions | Yield |
|---|---|
| With ethanol at 20℃; for 15h; | 94% |
| Conditions | Yield |
|---|---|
| With pyridine; hydrogenchloride; hydroxylamine hydrochloride; hydroxylamine In tetrahydrofuran; ethanol; dichloromethane; water; toluene | A n/a B 78% |
| Conditions | Yield |
|---|---|
| With hydroxylamine; sodium hydroxide In water at 20℃; for 3.7h; Time; | 62.3% |
| Conditions | Yield |
|---|---|
| With diethyl ether; hydroxylamine |
| Conditions | Yield |
|---|---|
| With hydroxylamine sulfate | |
| With hydroxylamine hydrochloride |
| Conditions | Yield |
|---|---|
| With hydroxylamine hydrochloride; water |
| Conditions | Yield |
|---|---|
| With hydroxylamine hydrochloride; water | |
| With Fe(3+), Cu(2+), H2SO4 In not given other Radiation; 20°C; vac.; X-ray irradiatin; concn. of urea 4.6 until 9.1 M in 0.1 N H2SO4; |
| Conditions | Yield |
|---|---|
| With sodium hydroxide; hydroxylamine hydrochloride | |
| With potassium hydroxide; hydroxylamine sulfate |
| Conditions | Yield |
|---|---|
| With sodium hydroxide; hydroxylamine hydrochloride |
- 343338-28-3(S)-(-)-2-Methyl-2-Propanesulfinamide
- 104-47-2Benzeneacetonitrile,4-methoxy-
- 119-53-9Benzoin
- 111128-12-22-(4-Bromomethyl)phenylpropionic acid
- 9004-66-4Iron dextran
- 82640-04-8Methanone,[6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-,hydrochloride (1:1)
- 40615-36-9Benzene,1,1'-(chlorophenylmethylene)bis[4-methoxy-
- 105-58-8Diethyl carbonate
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
What can I do for you?
Get Best Price
Consensus Reports
Specification
The Hydroxyurea, with the CAS registry number 127-07-1, is also known as Urea, N-hydroxy-. It belongs to the product categories of Miscellaneous Biochemicals; Pharmacetical; Aliphatics; Nucleotides and Nucleosides; Hydroxylamines; Hydroxylamines (N-Substituted); Bases & Related Reagents; Nitric Oxide Reagents; Nucleotides; Carbonyl Compounds; Organic Building Blocks; Ureas; DNA Synthesis Inhibitors; DNA Synthesis Inhibitors Cancer Research; Antitumor Agents; Apoptosis and Cell Cycle; DNA Metabolism; Aids Aided Treatment; Amines. Its EINECS registry number is 204-821-7. This chemical's molecular formula is CH4N2O2 and molecular weight is 76.05. What's more, its IUPAC name is called 1-Hydroxyurea. It should be stored in a cool, dry and well-ventilated place. This chemical can be prepared by Ethyl Carbamate with hydroxylamine hydrochloride.
Physical properties about Hydroxyurea are: (1)ACD/LogP: -1.8; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): -1.80; (4)ACD/LogD (pH 7.4): -1.80; (5)ACD/BCF (pH 5.5): 1.00; (6)ACD/BCF (pH 7.4): 1.00; (7)ACD/KOC (pH 5.5): 2.50; (8)ACD/KOC (pH 7.4): 2.49; (9)#H bond acceptors: 4; (10)#H bond donors: 4; (11)#Freely Rotating Bonds: 1; (12)Polar Surface Area: 75.35 Å2; (13)Index of Refraction: 1.501; (14)Molar Refractivity: 15.376 cm3; (15)Molar Volume: 52.161 cm3; (16)Polarizability: 6.096×10-24 cm3; (17)Surface Tension: 69.72 dyne/cm; (18)Density: 1.458 g/cm3.
Uses of Hydroxyurea: (1) it is used as an anticancer drug; (2) it is used to produce other chemicals. For example, it can react with 2-methyl-3-oxo-butyric acid ethyl ester to get 1-hydroxy-5,6-dimethyl-1H-pyrimidine-2,4-dione. This reaction needs reagent NaOEt and solvent ethanol at ambient temperature. The reaction time is 72 hours. The yield is 60 %.
When you are dealing with this chemical, you should be very careful. This chemical may cause damage to health at low levels and may cause heritable genetic damage. It has a carcinogenic effect and may cause harm to the unborn child. Therefore, you should wear suitable protective clothing and gloves. In addition, you should avoid exposuring and obtain special instructions before using it. In case of contacting with eyes, you should rinse immediately with plenty of water and seek medical advice. And in case of accident or if you feel unwell seek medical advice immediately.
You can still convert the following datas into molecular structure:
(1) SMILES: O=C(N)NO
(2) InChI: InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)
(3) InChIKey: VSNHCAURESNICA-UHFFFAOYSA-N
The toxicity data is as follows:
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| dog | LD50 | intravenous | > 1gm/kg (1000mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 682, 1992. | |
| dog | LD50 | oral | > 2gm/kg (2000mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 682, 1992. | |
| human | TDLo | intravenous | 86mg/kg (86mg/kg) | GASTROINTESTINAL: NAUSEA OR VOMITING BLOOD: OTHER CHANGES | Cancer Chemotherapy Reports, Part 1. Vol. 57, Pg. 369, 1973. |
| human | TDLo | oral | 80mg/kg/D (80mg/kg) | BLOOD: NORMOCYTIC ANEMIA BLOOD: LEUKOPENIA BLOOD: THROMBOCYTOPENIA | Cancer Chemotherapy Reports. Vol. 29, Pg. 103, 1963. |
| man | TDLo | oral | 14mg/kg (14mg/kg) | Annals of Pharmacotherpy. Vol. 29, Pg. 132, 1995. | |
| man | TDLo | oral | 450mg/kg/21D- (450mg/kg) | GASTROINTESTINAL: NAUSEA OR VOMITING LUNGS, THORAX, OR RESPIRATION: "FIBROSIS, FOCAL (PNEUMOCONIOSIS)" | Netherlands Journal of Medicine. Vol. 51, Pg. 110, 1997. |
| man | TDLo | unreported | 64mg/kg/3D-I (64mg/kg) | LUNGS, THORAX, OR RESPIRATION: DYSPNEA LUNGS, THORAX, OR RESPIRATION: COUGH | Australian and New Zealand Journal of Medicine. Vol. 28, Pg. 347, 1998. |
| mouse | LD10 | subcutaneous | 2400mg/kg (2400mg/kg) | European Journal of Cancer. Vol. 10, Pg. 667, 1974. | |
| mouse | LD50 | intraperitoneal | 5800mg/kg (5800mg/kg) | Cancer Research. Vol. 39, Pg. 3575, 1979. | |
| mouse | LD50 | intravenous | 2350mg/kg (2350mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 682, 1992. | |
| mouse | LD50 | oral | 7330mg/kg (7330mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 682, 1992. | |
| rat | LD50 | intraperitoneal | > 4700mg/kg (4700mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 18, Pg. 645, 1968. | |
| rat | LD50 | intravenous | 4730mg/kg (4730mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 682, 1992. | |
| rat | LD50 | oral | 5760mg/kg (5760mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 682, 1992. | |
| rat | LD50 | unreported | 4300mg/kg (4300mg/kg) | Proceedings of the American Association for Cancer Research. Vol. 4, Pg. 10, 1963. | |
| women | TDLo | oral | 600mg/kg/30D- (600mg/kg) | Netherlands Journal of Medicine. Vol. 51, Pg. 110, 1997. | |
| women | TDLo | oral | 600mg/kg/30D- (600mg/kg) | GASTROINTESTINAL: NAUSEA OR VOMITING GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Netherlands Journal of Medicine. Vol. 51, Pg. 110, 1997. |